In the BioHarmony Drug Report Database
Belantamab mafodotin-blmf
Blenrep (belantamab mafodotin) is an antibody pharmaceutical. Belantamab mafodotin was first approved as Blenrep on 2020-08-05. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target tumor necrosis factor receptor superfamily member 17.
Trade Name
|
Blenrep |
|---|---|
Common Name
|
belantamab mafodotin |
ChEMBL ID
|
CHEMBL4298209 |
Indication
|
multiple myeloma |
Drug Class
|
Synthetic analogs of the dolastatin series; monoclonal antibodies: tumors |
Image (chem structure or protein)
